A phase I clinical trial of immunotherapy with interferon-? gene-modified autologous melanoma cells

Abstract

These data suggest that gene therapy with IFN-gamma-transduced melanoma cells is safe and worthy of further investigation in patients with less advanced stage malignant melanoma. The ability to monitor changes in the humoral responses of the immunized patients has been demonstrated.